Inhibrx Biosciences, Inc.
INBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $222,929 | $1,790,940 | $988,261 | $1,659,897 |
| - Cash | $152,596 | $277,924 | $273,865 | $131,301 |
| + Debt | $8,048 | $210,141 | $207,102 | $70,470 |
| Enterprise Value | $78,381 | $1,723,157 | $921,498 | $1,599,066 |
| Revenue | $200 | $1,800 | $2,192 | $7,125 |
| % Growth | -88.9% | -17.9% | -69.2% | – |
| Gross Profit | -$2,085 | $609 | -$107,994 | $4,437 |
| % Margin | -1,042.5% | 33.8% | -4,926.7% | 62.3% |
| EBITDA | $1,703,350 | -$206,693 | -$125,817 | -$75,369 |
| % Margin | 851,675% | -11,482.9% | -5,739.8% | -1,057.8% |
| Net Income | $1,687,572 | -$241,361 | -$145,226 | -$81,768 |
| % Margin | 843,786% | -13,408.9% | -6,625.3% | -1,147.6% |
| EPS Diluted | 116.58 | -5.12 | -3.62 | -2.15 |
| % Growth | 2,377% | -41.4% | -68.4% | – |
| Operating Cash Flow | -$194,409 | -$193,309 | -$115,301 | -$80,323 |
| Capital Expenditures | -$2,597 | -$4,593 | -$686 | -$864 |
| Free Cash Flow | -$197,006 | -$197,902 | -$115,987 | -$81,187 |